Current and historical daily PE Ratio for Eli Lilly and Co (
) from 1990 to Apr 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Eli Lilly and stock (LLY) PE ratio as of Apr 27 2024 is 129.
More Details
Eli Lilly and Co (LLY) PE Ratio (TTM) Chart
Eli Lilly and Co (LLY) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1217
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Eli Lilly and PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-27 | 129.0 | 2024-02-23 | 135.3 |
| 2024-04-26 | 129.0 | 2024-02-22 | 135.4 |
| 2024-04-25 | 127.5 | 2024-02-21 | 131.2 |
| 2024-04-24 | 128.8 | 2024-02-20 | 132.9 |
| 2024-04-23 | 131.1 | 2024-02-16 | 137.5 |
| 2024-04-22 | 128.6 | 2024-02-15 | 133.3 |
| 2024-04-19 | 127.7 | 2024-02-14 | 133.2 |
| 2024-04-18 | 131.2 | 2024-02-13 | 130.7 |
| 2024-04-17 | 132.0 | 2024-02-12 | 129.7 |
| 2024-04-16 | 131.3 | 2024-02-09 | 130.2 |
| 2024-04-15 | 132.0 | 2024-02-08 | 129.4 |
| 2024-04-12 | 132.2 | 2024-02-07 | 127.6 |
| 2024-04-11 | 133.6 | 2024-02-06 | 124.0 |
| 2024-04-10 | 134.0 | 2024-02-05 | 124.2 |
| 2024-04-09 | 133.2 | 2024-02-02 | 117.4 |
| 2024-04-08 | 136.7 | 2024-02-01 | 116.2 |
| 2024-04-05 | 137.9 | 2024-01-31 | 113.5 |
| 2024-04-04 | 135.1 | 2024-01-30 | 113.4 |
| 2024-04-03 | 136.5 | 2024-01-29 | 113.4 |
| 2024-04-02 | 134.4 | 2024-01-26 | 112.4 |
| 2024-04-01 | 133.8 | 2024-01-25 | 110.4 |
| 2024-03-28 | 136.8 | 2024-01-24 | 111.5 |
| 2024-03-27 | 136.9 | 2024-01-23 | 110.7 |
| 2024-03-26 | 136.3 | 2024-01-22 | 111.0 |
| 2024-03-25 | 136.0 | 2024-01-19 | 110.5 |
| 2024-03-22 | 135.5 | 2024-01-18 | 109.6 |
| 2024-03-21 | 135.5 | 2024-01-17 | 110.6 |
| 2024-03-20 | 135.9 | 2024-01-16 | 111.6 |
| 2024-03-19 | 135.9 | 2024-01-12 | 113.1 |
| 2024-03-18 | 134.1 | 2024-01-11 | 111.8 |
| 2024-03-15 | 132.6 | 2024-01-10 | 110.8 |
| 2024-03-14 | 133.8 | 2024-01-09 | 110.0 |
| 2024-03-13 | 133.3 | 2024-01-08 | 110.1 |
| 2024-03-12 | 132.8 | 2024-01-05 | 108.8 |
| 2024-03-11 | 129.2 | 2024-01-04 | 108.1 |
| 2024-03-08 | 134.0 | 2024-01-03 | 108.6 |
| 2024-03-07 | 137.2 | 2024-01-02 | 104.2 |
| 2024-03-06 | 137.1 | 2023-12-29 | 102.5 |
| 2024-03-05 | 136.8 | 2023-12-28 | 102.2 |
| 2024-03-04 | 139.3 | 2023-12-27 | 107.3 |
| 2024-03-01 | 137.6 | 2023-12-26 | 105.3 |
| 2024-02-29 | 132.6 | 2023-12-22 | 105.3 |
| 2024-02-28 | 133.3 | 2023-12-21 | 105.5 |
| 2024-02-27 | 134.5 | 2023-12-20 | 105.2 |
| 2024-02-26 | 135.8 | 2023-12-19 | 107.0 |
Eli Lilly and Co (LLY) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Eli Lilly and Co
NAICS : 325412
SIC : 2834
ISIN : US5324571083
Share Class Description:
LLY: Ordinary SharesCompare
Compare
Traded in other countries / regions
LLY.USALLY.CanadaLILY34.BrazilLLY.GermanyLLY.SwitzerlandLLY.ArgentinaLLY.Mexico1LLY.ItalyLLYC.AustriaLLYz.UKLLY.France IPO Date
1970-07-09Description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers